Helga TX Tablet SR is a sustained-release formulation combining Tranexamic Acid (250 mg), L-Glutathione Reduced (500 mg), and L-Ascorbic Acid (250 mg), designed to provide synergistic therapeutic benefits primarily in dermatological and hemostatic applications. Tranexamic Acid, a synthetic antifibrinolytic agent, inhibits plasminogen activation, thereby reducing excessive bleeding and contributing to the management of hyperpigmentation disorders by modulating melanogenesis. L-Glutathione Reduced, a potent intracellular antioxidant, plays a critical role in neutralizing free radicals, enhancing cellular detoxification, and promoting skin lightening through its inhibitory effect on tyrosinase activity. L-Ascorbic Acid (Vitamin C) further supports antioxidant defense mechanisms, collagen synthesis, and skin repair processes, while also enhancing the efficacy of glutathione. The sustained-release mechanism ensures prolonged plasma concentration, optimizing therapeutic outcomes and improving patient compliance. Helga TX Tablet SR is indicated for the adjunctive treatment of melasma, post-inflammatory hyperpigmentation, and other pigmentary abnormalities, as well as for conditions requiring antifibrinolytic intervention. It should be used under medical supervision, considering contraindications such as active thromboembolic disease or hypersensitivity. Regular monitoring is advised to evaluate therapeutic response and detect any adverse effects.